Age–period–cohort analysis of past 12‐month cannabis use in Germany (1995–2021)
Addiction · 2025
DOI: 10.1111/add.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, 2025. Verfasst von Natalie S Schöllner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Statistik, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. Hauptthemen laut MEDLINE: Marijuana Use. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Gesundheit.
Abstract (Originalsprache)
Background and Aims In 2024, cannabis was partially legalized for recreational purposes in Germany. With a growing prevalence of persons who used cannabis in the past 12 months, and the health risks associated with cannabis use, it is imperative to examine usage behavior patterns in greater detail. The present analysis measured the impact of age, time period and birth cohort on the prevalence of cannabis consumption in the past 12 months in Germany.
Design
Longitudinal study using data from 10 waves (1995–2021) of the German Epidemiological Survey of Substance Abuse (ESA), a cross‐sectional nationally representative household survey of individuals between the ages of 18 and 59 or 64 years.
Setting
Germany.
Participants
N total = 78 678 German‐speaking adults between the ages of 18 and 59 years.
Measurements
Self‐report of cannabis use in the last 12 months as well as alcohol use and smoking conventional tobacco products in the last 30 days.
Findings
We employed binary logistic regression using a generalized additive model to examine age, period and cohort effects, as well as covariate effects on past 12‐month cannabis use. Over time, both period and cohort had an increasing effect, while an increase in age corresponded to a decrease in prevalence. Specifically, the odds ratio (OR) for cannabis use decreased from 9.44 [95% confidence interval (CI) = 8.17−10.9] at age 18 years to 0.13 (95 CI = 0.10−0.17) at age 59 years. Period effects also showed an increase, with the OR rising from 0.33 (95% CI = 0.26−0.43) in 1995 to 2.96 (95% CI = 2.55−3.43) in 2021, while cohort effects increased from 0.02 (95% CI = 0.001−0.05) for those born in 1936 to 16.69 (95% CI = 13.8−20.8) for those born in 2002. Additionally, persons using cannabis had a higher likelihood of also drinking alcohol and smoking conventional tobacco products in the last 30 days.
Conclusions
In Germany, the odds of being a past‐12‐month cannabis consumer appears to decline with increasing age, indicating that only a small proportion of consumers engage in cannabis use throughout their whole lives, with a peak prevalence occurring at a younger age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut für Statistik, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
- Institut für Therapieforschung (IFT), Centre for Mental Health and Addiction Research, Munich, Germany.
- Department of Psychiatry and Psychotherapy, Cannabinoid Research Group, University Hospital, LMU München, Munich, Germany.
- Department of Clinical Psychology and Psychotherapy, Charlotte Fresenius University, Munich, Germany.
ORCID-Profile: Natalie S Schöllner, Eva-Maria Krowartz, Sally Olderbak
Förderung
- Bundesministerium für Gesundheit
Zitieren
APA
Schöllner, N. S., Glos, A., Möckl, J., Krowartz, E. M., Hoch, E., & Olderbak, S. (2025). Age–period–cohort analysis of past 12‐month cannabis use in Germany (1995–2021). Addiction. https://doi.org/10.1111/add.70087
Vancouver
Schöllner NS, Glos A, Möckl J, Krowartz EM, Hoch E, Olderbak S. Age–period–cohort analysis of past 12‐month cannabis use in Germany (1995–2021). Addiction. 2025. doi:10.1111/add.70087
BibTeX
@article{Schllner2025,
author = {Schöllner, Natalie S and Glos, Adrian and Möckl, Justin and Krowartz, Eva-Maria and Hoch, Eva and Olderbak, Sally},
title = {Age–period–cohort analysis of past 12‐month cannabis use in Germany (1995–2021)},
journal = {Addiction},
year = {2025},
doi = {10.1111/add.70087}
}
EUVIMED